Dr. Reddy's Laboratories launches Carmustine for Injection, USP in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Carmustine for Injection, USP, a therapeutic equivalent generic version of BiCNU® (carmustine for injection) approved by the U.S. Food and Drug Administration (USFDA).

The BiCNU® brand and generic market had U.S. sales of approximately $19.4 million MAT for the most recent twelve months ending in August 2021 according to IQVIA Health*.

Dr. Reddy's Carmustine for Injection, USP is a lyophilized powder available as a package which includes a single-dose vial containing 100 mg Carmustine USP and a vial containing 3 mL sterile diluent.

Shares of Dr. Reddy's Laboratories Limited was last trading in BSE at Rs. 4959.70 as compared to the previous close of Rs. 4931.30. The total number of shares traded during the day was 28053 in over 4309 trades.

The stock hit an intraday high of Rs. 5007.00 and intraday low of 4922.30. The net turnover during the day was Rs. 139504868.00.

Source : Equity Bulls

Keywords

DrReddysLaboratories INE089A01023 Pharmaceuticals